Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
9.19
-0.34 (-3.57%)
At close: Jun 5, 2025, 4:00 PM
9.19
0.00 (-0.02%)
After-hours: Jun 5, 2025, 7:48 PM EDT
Organon & Co. Revenue
Organon & Co. had revenue of $1.51B in the quarter ending March 31, 2025, a decrease of -6.72%. This brings the company's revenue in the last twelve months to $6.29B, down -0.84% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.29B
Revenue Growth
-0.84%
P/S Ratio
0.38
Revenue / Employee
$629,400
Employees
10,000
Market Cap
2.39B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OGN News
- 1 day ago - OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law - Accesswire
- 2 days ago - OGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal Deadline - Accesswire
- 3 days ago - Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein - PRNewsWire
- 5 days ago - OGN CLASS NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law before July 22 Court Deadline (NYSE:OGN) - GlobeNewsWire
- 6 days ago - Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein - GlobeNewsWire
- 7 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN - PRNewsWire
- 9 days ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Organon & Co. (OGN) - GlobeNewsWire
- 9 days ago - US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection - Business Wire